Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Read More
The Quest for Treatments to Keep Weight Off After Ozempic
Obesity researchers and companies turn toward helping people maintain losses.
Read MoreFractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Read More
Fractyl Health Announces Pricing of Initial Public Offer
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today announced the pricing of its initial public offering of ...
Read MoreFractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in it's Rejuva® GLP-1 Gene Therapy Platform
Read MoreFractyl Health Announces New Pooled Analysis from Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure
Read More
A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On It
THERE’S A MAJOR downside to semaglutide, the drug originally developed for diabetes and now prescribed for weight loss under the brand names Ozempic and Wegovy: People often stop...
Read MorePIONEERING BREAKTHROUGH THERAPIES TO TREAT OBESITY, WEIGHT MAINTENANCE AFTER GLP-1S, AND TYPE 2 DIABETES (T2D)
Our vision is to develop breakthrough therapies that have the potential to prevent and reverse obesity, support durable weight maintenance after GLP-1 pharmacotherapy, and put T2D into remission . At Fractyl Health, we are singularly focused on developing therapies that are designed to target root causes of obesity and T2D, and delivering those therapies to patients as broadly and rapidly as possible. Our two therapies – Rejuva and Revita – have the potential to become a comprehensive approach to prevention and remission of both obesity and T2D, with the possibility of eradicating T2D entirely.
REVITA®
Revita is an outpatient procedural therapy designed to durably modify duodenal dysfunction via hydrothermal ablation in order to restore metabolic health.
In addition, early evidence suggests that Revita has the potential to provide durable weight maintenance after GLP-1s.
Learn About RevitaSEEKING A MAJOR ADVANCE IN GLP-1 MEDICINES WITH PANCREATIC GENE THERAPY
Rejuva is a novel, locally administered, AAV gene therapy platform currently in preclinical development to improve islet function. We believe the platform represents a major advance in incretin-based therapies. PGTx is designed to potentially enable long-term remission of T2D and obesity by durably altering metabolic hormone response in the pancreatic islet cells of patients with those diseases.
Learn about Rejuva
